Table 2.
Summary of Drug Loading and In Vitro Drug Releasea
| Formulation | Drug loading (%) | Burst release % (duration in days) | Controlled release % (duration in days) |
|---|---|---|---|
| Uncoated Dexa MS (0.25 mg/ml) | 77 ± 8% | 19% (1) | 100% (22) |
| (PAH/PSS)1 coated Dexa (0.25 mg/ml) MS | 11% (1) | 79% (30) | |
| (25P+75CP) Dexa (0.25 mg/ml) MS | 6.5% (1) | 100% (30) | |
| (50P+50CP) (0.25 mg/ml) Dexa MS | 10.5% (1) | 86.5% (30) | |
| (75P+25CP) (0.25 mg/ml) Dexa MS | 16.5% (1) | 75.7% (30) | |
| Uncoated Diclo MS (0.50 mg/ml) | 79 ± 5% | 8.5% (2) | 100% (30) |
| Uncoated Diclo MS (0.75 mg/ml) | 11.5% (2) | 100% (35) | |
| Uncoated Diclo MS (1 mg/ml) | 20 % (2) | 86.7% (30) | |
| (PAH/PSS)1 coated (0.75 mg/ml) Diclo MS | 9.5% (2) | 50.9% (30) | |
| (PAH/PSS)2 coated (0.75 mg/ml) Diclo MS | 9.0% (2) | 34.1% (30) |
a
MS, microspheres; Dexa, dexamethasone; Diclo, diclofenac; P, uncoated MS; CP, polyelectrolyte coated